Resource item | Mean | Sensitivity analyses | Rationale | ||
---|---|---|---|---|---|
Lower | Upper | Distribution | |||
Acute treatment | |||||
Number of days of acute treatment (i.e. LMWH) required by a DVT patient | 9.6 | 6 | 10 | Dirichlet | EINSTEIN DVT [25] |
SIGN guidelines [15] | |||||
Number of days of acute treatment (i.e. LMWH) required by a PE patient | 9.7 | 7 | 13 | Dirichlet | Mean duration from EINSTEIN PE [26] |
Proportion of patients who self-inject LMWH (%) | 92 | 64.40 | 100 | Beta | The point estimate is taken from the assumptions in NICE CG92 [56]. The sensitivity range is an assumption |
Proportion of remaining patients who require nurse assistance at home (%) | 80 | 60 | 100% | Beta | These values are assumptions based on inputs determined for the NICE CG92 model |
INR monitoring while on LMWH/VKA | |||||
Visits in first 3Â months | 9 | 5 | 15 | Gamma | |
Visits each 3Â months thereafter | 5 | 2.5 | 10 | Gamma | |
Recurrent VTE: proportion treated as outpatients rather than inpatients | |||||
Recurrent DVT patients (%) | 69 | 50 | 100 | Beta | SIGN guidelines [15] |
Incident PE patients (%) | 17 | 0 | 30 | Beta | Survey data |
Other | |||||
Proportion of patients requiring NHS-funded transportation (%) | 8.55 | 6 | 11 | Beta | Survey data |
Proportion of CTEPH patients who require PEA (%) | 68.40 | 64.20 | 72.60 | Beta | 321 of 469 patients from Condliffe 2008 [43] |
Length of admission post DVT, days | Â | Â | Â | Â | van Bellen 2014 [52] |
LMWH/VKA | 8* | 4 | 10 | Â | Â |
Rivaroxaban | 5* | 3 | 9 | Â | Â |
Length of admission post PE, days | Â | Â | Â | Â | van Bellen 2014 [52] |
LMWH/VKA | 7* | 5 | 10 | Â | Â |
Rivaroxaban | 6* | 4 | 9 | Â | Â |